摘要
目的研究重组人尿激酶原对ST段抬高型急性心肌梗死(AMI)患者血浆纤溶因子及血管再通的影响。方法选取2018年9月~2019年9月在我院诊治的106例ST段抬高型AMI患者为研究对象,采用随机数字表法分为对照组和观察组,各53例。对照组采用尿激酶治疗,观察组采用重组人尿激酶原治疗,比较两组临床血管再通率、治疗前后血浆纤溶因子指标[人组织纤溶酶原激活物(t-PA)、人纤溶酶原激活物抑制剂(PAI-1)]水平、ST段完全回落率、心脏事件和出血发生率及临床不良反应发生情况。结果观察组血管再通率为81.13%,高于对照组的67.92%(P<0.05);治疗后两组t-PA均高于治疗前,观察组高于对照组(P<0.05);治疗后两组PAI-1均低于治疗前,PAI-1低于对照组(P<0.05);观察组ST段完全回落率高于对照组,心脏事件和出血发生率均低于对照组(P<0.05);观察组不良反应总发生率为7.54%,低于对照组的16.98%(P<0.05)。结论重组人尿激酶原可提高ST段抬高型AMI血管再通率,促进血浆纤溶因子水平改善,提升ST段完全回落率,降低心脏事件和出血发生率,且不良反应少,安全性良好。
Objective To study the effect of recombinant human urokinase on plasma fibrinolytic factor and vascular recanalization in patients with ST-segment elevation acute myocardial infarction(AMI).Methods A total of 106 patients with ST-segment elevation AMI diagnosed and treated in our hospital from September 2018 to September 2019 were selected as the research object.They were divided into a control group and an observation group with a random number table method,each with 53 cases.The control group was treated with urokinase,and the observation group was treated with recombinant human urokinase.The clinical vascular recanalization rate,plasma fibrinolytic factor index before and after treatment were compared between the two groups[human tissue plasminogen activator(t-PA),human fibrinogen Plasminogen activator inhibitor(PAI-1)]level,ST segment complete fall rate,heart event and bleeding rate,and clinical adverse reactions.Results The recanalization rate of the observation group was 81.13%,which was higher than 67.92% of the control group(P<0.05);after treatment,the t-PA of both groups was higher than before treatment,and the observation group was higher than the control group(P<0.05);after treatment PAI-1 in both groups was lower than before treatment,and PAI-1 was lower than the control group(P<0.05);the rate of complete ST segment fallback in the observation group was higher than that in the control group,and the incidence of cardiac events and bleeding was lower than that in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 7.54%,lower than 16.98%in the control group(P<0.05).Conclusion Recombinant human prourokinase can increase the vascular recanalization rate of ST-segment elevation AMI,promote the improvement of plasma fibrinolytic factor level,increase the ST-segment complete fall rate,reduce the incidence of cardiac events and bleeding,and have fewer adverse reactions and good safety.
作者
栾学冰
LUAN Xue-bing(Department of Cardiology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
出处
《医学信息》
2020年第13期156-157,共2页
Journal of Medical Information
关键词
重组人尿激酶原
急性心肌梗死
血浆纤溶因子
血管再通率
Recombinant human prourokinase
Acute myocardial infarction
Plasma fibrinolytic factor
Revascularization rate
